Theintroductionofimmunotherapywithcheckpointreceptorblockadehaschanged the treatment of advanced cancers, at times inducing prolonged remission. 
| INTRODUCTION
Immunotherapy represents a breakthrough in the management of This article is part of a series of reviews covering Checkpoint Inhibitors and Cancer
Immunotherapy appearing in Volume 276 of Immunological Reviews. sure. [4] [5] [6] Lack of CD4 help has also been reported to impair sustained effectiveanti-viralCD8responsesduringchronicinfection, 7 an obser- throughinductionofsustainedexpressionofthetranscriptionBATF, whichcooperateswithIRF-4tomaintainBlimp-1expression,andas such CD8 effector functions.
| T-CELL EXHAUSTION
T
10
Exposure to type I interferons (IFN)
hasbeenproposedtohavetime-dependentopposingeffectsonexhaustioninduction:indeed,whilepromotingCD8effectordifferenti-ationatearlytimepointsinthecourseofaninfection,chronicIFNβ stimulation is detrimental to anti-viral CD8 T-cell responses. While the precise mechanism has not yet been determined, there are indicationsforanindirectrolethroughCD4T-cellhelp. 11, 12 It is important to stressthatexhaustedcellsarenotentirelyinerttowardtheinfection:
indeed,theireliminationfromtheantigen-specificpoolmightresultin exacerbationofadormantchronicinfection.Therefore,exhaustionis thoughttorepresentaco-evolutionarycompromisebetweenhostand pathogens, especially viruses that can enter a latency phase, to establish an impasse and prevent immunopathological damage. 
| Expression of co-inhibitory receptors

| Tumor biology
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The platelet-derived growth factor receptor α (PDGFRA) locus alsoundergoesgeneamplificationin15%ofglioblastomas;similarto EGFR,thegeneamplificationisassociatedwithpointmutationsleadingtoaconstitutivelyactiveform. 66 PDGFRA signaling promotes aggressive tumor growth, probably through both autocrine and paracrine mechanisms. Tumor cells that engage in a high proliferative activity requiretoundergoakeymetabolicchangeknownastheWarburgeffect. 67 In this process, tumor cells derive energy from a high rate of 
| Current therapeutic strategies
The first line of intervention for newly diagnosed patients with a glioblastoma is maximal safe resection of the tumor, which, on top of relieving compression-related symptoms, can improve overall survival, provided that a threshold of extent of resection is met. Multiple cell types in glioblastoma can secrete the immune suppressor cytokine TGFβ, which is found at elevated levels in the serum of patients with glioblastoma, and has been proposed as the major driver of Treg proliferation. Moreover, other cytokines produced in thetumormicroenvironmentincludeIL-10,prostaglandinE-2,andthe enzyme IDO. 
| The role of Tregs
In addition to being increased in the periphery, Tregs infiltrate glioblastoma, a feature shared with other cancers such as melanoma, non-small cell lung cancer (NSCLC), gastric and ovarian cancer.
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Moreover,inglioblastomahighfrequenciesofintra-tumorTregshave been established as a predictor of poor prognosis. 92 It has been proposed that the tumor recruits Tregs from the periphery through secretionofthechemokinesCCL22andCCL2,whichcouldbeinduced by hypoxic conditions. 
| CHECKPOINT RECEPTOR IMMUNOTHERAPY
| Clinical success in other tumors
The first checkpoint receptor inhibitor to enter cancer immunotherapy has been a monoclonal antibody against CTLA-4, 
| Role of checkpoint receptors in Treg function
| Autoimmune-like adverse reactions
It has long been known that blocking CTLA-4 co-stimulatory path- and antigen-specific CD8T cells in patientswith a given haplotype.
Twopatientsalsodevelopedconcomitantautoimmunethyroiditis.
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Therefore, interfering with CTLA-4 and PD-1 to reinvigorate antitumorT-cellresponsesmayinduceseriousautoimmune-likereactions.
| Single or combination immunotherapy?
Functional analysis of co-inhibitory receptors suggests a degree of redundancy that may be tissue-specific leading to a hierarchical modeltoexplainthemultiplicityofcheckpointsforcontrolofT-cell responses.
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AsdepictedinFigure2,PD-1andCTLA-4mayrepresent
thefirstlinesofself-tolerancewiththefatalimmunehyperactivation inknock-outanimals,aswellastheimmune-relatedadversereactions oftherapeuticstrategiestargetingthesemolecules.TIGIT,Tim-3and LAG3,appeartoregulatemorespecifictypesofimmuneresponses.
F I G U R E 2 Roleofdifferentcoinhibitory receptors in control of autoimmunityandanti-tumorimmunity. Blockadeofdifferentreceptorselicits hierarchical levels of tumor rejection and autoimmune complications, as reflected by the universal versus specific inhibitory activity
For example, the ligands of Tim-3, CEACAM-1 and Galectin-9, are highly expressed in the gut, 153 while the newly identified alternative ligand of LAG-3, LSECtin, is abundant in the liver, suggesting a tissue-specific role for these receptors. Likewise, CD155 expression has been characterized in the Peyer's patches 154 as well as in neurons, 155 consistent with its role as receptor for the poliovirus.
Moreover,theinhibitoryfunctionofTIGITisspecificallydirectedto
Th1 and Th17 responses, sparing Th2 immunity. Moreover, mice deficientforthesereceptorsdisplayamilderphenotype.Thustargeting TIGIT,LAG3andTim-3mayallowamoreorgan-specificstrategyfor cancer immunotherapy.
Based on these observations, it seems reasonable to vigorously pursueotherco-inhibitoryreceptorsasatherapeuticstrategy.LAG-3
blockade was initially shown to enhance tumor vaccination in animal models, 156 and to synergizewith PD-1 in models of chronic infection. 
Finally,theopportunityoftargetingmultiplecheckpointreceptors
is suggested by a recent study showing that in both mouse models and patients with adenocarcinoma, resistance to anti-PD-1 therapy was associatedwithincreasedexpressionofTim-3.Ofnote,intheanimal model,blockingTim-3afterfailureofanti-PD-1therapywassuccess-fulinenhancingrejectionofthetumor. 163 Thus, this study indicates thatthepartialfunctionaloverlapbetweenco-inhibitoryreceptorscan beexploitedbytumorcellsasanescapestrategy,similartoresistance to chemotherapy.
| CHECKPOINT IMMUNOTHERAPY FOR GLIOBLASTOMA
When considering the application of checkpoint immunotherapy to glioblastoma, issues related to the CNS localization of the cancer need to be taken into account. As previously mentioned, the blood-brain barrier is often disrupted in glioblastoma; nevertheless, On the other hand, it has been suggested that lymphopenia may reduce Treg frequency eliminating homeostatic brakes to T effector cellproliferation.
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Specifically,itisknownthatimmunedeficienciescanbeaccompaniedbyautoimmuneandinflammatoryreactions.
Thus, although more studies are needed, it seems reasonable to estab- 
ThisresultisconsistentwiththeroleofPD-1in
blocking IFNG transcription through nuclear localization of FoxO1.
Although the functionality of Tregs during Nivolumab ® therapy was not assessed, and the study was not powered to establish efficacy,
thisresultrepresentsaproofofconceptthatPD-1signalingrepresses
Th-1reprogrammingofTregsinglioblastoma,andthustargetingPD-1 could destabilize the regulatory program. Nevertheless, it should be kept in mind that IFNγsignalinginducesPD-L1expressionontumor cells, 171, 172 andthatPD-L1hasbeenseentosustainthemetabolism oftumorcellsevenintheabsenceofPD-1ligation. 17 Therefore, the 
